🇺🇸 FDA
Patent

US 7153514

Use of botulinum toxin therapy for prostatic hyperplasia and related disorders

granted A61KA61K31/165A61K31/529

Quick answer

US patent 7153514 (Use of botulinum toxin therapy for prostatic hyperplasia and related disorders) held by The Regents of the University of Colorado expires Mon Dec 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Dec 26 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/165, A61K31/529, A61K38/1703, A61K38/4893